For the twelve months ended Sep 30, 2026, iBio Inc. reported $1.07M of revenue and -$34.88M of net income.
IBIO revenueQ1 2027$1.07M
- Quarter YoY
- +975.0%
- FY YoY
- -75.0%
- 5Y CAGR
- -46.9%
- 10Y CAGR
- -20.1%
IBIO revenue was $1.07M in fiscal Q1 2027 (ended Sep 30, 2026), up 975.0% from a year earlier. For the full fiscal 2026 it was $100.0K, down 75.0% from fiscal 2025. Compound annual growth was -46.9% over 5 years and -20.1% over 10 years.
IBIO net incomeQ1 2027-$7.55M
IBIO net income was -$7.55M in fiscal Q1 2027 (ended Sep 30, 2026), compared with -$5.72M a year earlier. For the full fiscal 2026 it was -$33.04M, compared with -$18.38M in fiscal 2025.
IBIO EPSQ1 2027-$0.05
IBIO diluted EPS was -$0.05 in fiscal Q1 2027 (ended Sep 30, 2026). For the full fiscal 2026 it was -$0.32.
IBIO free cash flowQ1 2027-$9.49M
IBIO free cash flow was -$9.49M in fiscal Q1 2027 (ended Sep 30, 2026), compared with -$5.70M a year earlier. For the full fiscal 2026 it was -$23.80M, compared with -$15.32M in fiscal 2025.
Source: XBRL data iBio Inc. files with the SEC, latest filing dated Nov 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Sep 18, 2018; 1-for-20, first reported Feb 9, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.